title: Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
abstract: OBJECTIVE
  The present study evaluated the prognostic implications of insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER)-2 in patients with colorectal cancer (CRC).
  
  
  METHODS
  Our subjects were 91 patients who underwent surgery and subsequently received fluoropyrimidines. Expressions of IGF-1R, EGFR and HER-2 in primary lesions were analyzed immunohistochemically to determine the prognostic significance of these biomarkers.
  
  
  RESULTS
  Overexpression was found for IGF-1R in 48 tumors (53%), EGFR in 57 (63%) and HER-2 in 2 (2%). Overexpression of IGF-1R was significantly correlated with shorter survival from the start of first-line chemotherapy (p = 0.033). Overexpression of EGFR was a significant predictor of clinical response to fluoropyrimidines (p = 0.032). Multivariate analysis of potential prognostic factors showed that IGF-1R expression and worsened performance status were independent predictors of poor outcomes.
  
  
  CONCLUSIONS
  Our results suggest that anti-IGF-1R strategies may offer a useful approach in molecular therapy for CRC, which has the potential to improve outcomes.
authors.affiliation: Gastrointestinal Oncology Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takahari
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Yamada
authors.forename: Natuko T
authors.initials: NT
authors.lastname: Okita
authors.forename: Takuya
authors.initials: T
authors.lastname: Honda
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Hirashima
authors.forename: Junichi
authors.initials: J
authors.lastname: Matsubara
authors.forename: Atsuo
authors.initials: A
authors.lastname: Takashima
authors.forename: Ken
authors.initials: K
authors.lastname: Kato
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hamaguchi
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Shirao
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shimada
authors.forename: Tadakazu
authors.initials: T
authors.lastname: Shimoda
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D017526:Receptor, IGF Type 1 / Q000235:genetics*; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D005641:Tegafur; D066246:ErbB Receptors; D017526:Receptor, IGF Type 1; D005472:Fluorouracil